APOA1 and amyloidosis: Some groups have already begun to evaluate the potential benefits of apoA-I mimetics or reconstituted HDL in AD mice and have observed benefits with respect to amyloid pathology, CAA, and whole brain neuroinflammation [38–41], although not all studies found significant improvements or reported data for all of these pathologies.